PL3223807T3 - Metoda zapobiegania lub leczenia choroby lub stanu płuc - Google Patents

Metoda zapobiegania lub leczenia choroby lub stanu płuc

Info

Publication number
PL3223807T3
PL3223807T3 PL15862576T PL15862576T PL3223807T3 PL 3223807 T3 PL3223807 T3 PL 3223807T3 PL 15862576 T PL15862576 T PL 15862576T PL 15862576 T PL15862576 T PL 15862576T PL 3223807 T3 PL3223807 T3 PL 3223807T3
Authority
PL
Poland
Prior art keywords
treating
preventing
condition
pulmonary disease
pulmonary
Prior art date
Application number
PL15862576T
Other languages
English (en)
Inventor
Anantha HARIJITH
Viswanathan NATARAJAN
Roberto F. MACHADO
Jeffrey Jacobson
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Publication of PL3223807T3 publication Critical patent/PL3223807T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15862576T 2014-11-24 2015-11-24 Metoda zapobiegania lub leczenia choroby lub stanu płuc PL3223807T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083693P 2014-11-24 2014-11-24
EP15862576.4A EP3223807B1 (en) 2014-11-24 2015-11-24 Method of preventing or treating a pulmonary disease or condition
PCT/US2015/062332 WO2016085933A1 (en) 2014-11-24 2015-11-24 Method of preventing or treating a pulmonary disease or condition

Publications (1)

Publication Number Publication Date
PL3223807T3 true PL3223807T3 (pl) 2022-01-03

Family

ID=56074949

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15862576T PL3223807T3 (pl) 2014-11-24 2015-11-24 Metoda zapobiegania lub leczenia choroby lub stanu płuc

Country Status (5)

Country Link
US (1) US11026918B2 (pl)
EP (1) EP3223807B1 (pl)
ES (1) ES2895850T3 (pl)
PL (1) PL3223807T3 (pl)
WO (1) WO2016085933A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034243A1 (en) 2016-08-15 2018-03-22 The Children's Medical Center Corporation Apom-fc fusion proteins, complexes thereof with sphingosine l-phosphate (sip), and methods for treating vascular and non-vascular diseases
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
US12411144B2 (en) * 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
WO2020077206A1 (en) * 2018-10-12 2020-04-16 Children's Medical Center Corporation Apom-fc fusion proteins for treating lung diseases
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US8324237B2 (en) 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
ES2528451T3 (es) 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
JP2009503107A (ja) * 2005-08-04 2009-01-29 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤およびそれらの使用方法
US8372888B2 (en) 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
DE102008029734A1 (de) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate
US20120035268A1 (en) 2008-12-30 2012-02-09 Szulc Zdzislaw M Sphingo-guanidines and their use as inhibitors of sphingosine kinase
WO2011020116A1 (en) 2009-08-14 2011-02-17 University Of Virginia Patent Foundation Imidamide sphingosine kinase inhibitors
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
CN103703097A (zh) 2011-07-19 2014-04-02 日东电工株式会社 透明压敏粘合粘接剂和耐高温压敏粘合剂
WO2013119946A1 (en) * 2012-02-08 2013-08-15 Of Virginia Patent Foundation University Long chain base sphingosine kinase inhibitors
US9206423B2 (en) 2012-12-30 2015-12-08 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
KR102155068B1 (ko) * 2012-12-31 2020-09-11 사이언티픽 디자인 컴파니 인코포레이티드 고 선택성 산화에틸렌 촉매를 위한 스타트-업 공정
WO2014118556A2 (en) 2013-01-31 2014-08-07 Research Foundation Of The City University Of New York Selective inhibitors and allosteric activators of sphingosine kinase
WO2014157382A1 (ja) 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤

Also Published As

Publication number Publication date
US11026918B2 (en) 2021-06-08
EP3223807A4 (en) 2018-08-01
ES2895850T3 (es) 2022-02-22
US20170360749A1 (en) 2017-12-21
EP3223807B1 (en) 2021-09-15
EP3223807A1 (en) 2017-10-04
WO2016085933A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
LT3386511T (lt) Hantingtono ligos gydymo būdai
SG11201701723XA (en) Methods of treating liver disease
GB201701673D0 (en) Methods of well treatment
IL255423A0 (en) Methods for treating neurodegenerative disease
IL248856B (en) New treatment
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
PT3233071T (pt) Método de tratamento ou prevenção de doenças mediadas por ras
GB201410116D0 (en) Method of treatment
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
IL256109A (en) Methods for the treatment or prevention of protopathy
SG11201703184SA (en) A method of treatment
BR112017004533A2 (pt) método para tratamento de sarcoidose pulmonar
IL253028B (en) treatment method
GB201402036D0 (en) Method for determination of the status of a disease
GB201416832D0 (en) Methods of treatment
SG10202008024VA (en) Method for Treating Heart Failure
PL3220952T3 (pl) Sposób leczenia lub zapobiegania udarowi
PL3223807T3 (pl) Metoda zapobiegania lub leczenia choroby lub stanu płuc
IL252904A0 (en) Methods and factors for treating diseases
GB201521886D0 (en) A method of treating a well
SG11201609522TA (en) Methods for treating cardiovascular diseases
GB2543449B (en) Method of completing a well
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment